Navigation Links
Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/17/2011

ir market value of our investment in VGX International as of December 31, 2010, increase in other income from the revaluation of registered common stock warrants, increase in grant and miscellaneous revenue, and a decrease in general and administrative expenses.

Capital Resources As of December 31, 2010, cash and cash equivalents plus short-term investments in certificates of deposit were $21.8 million, compared to $30.3 million in cash and cash equivalents as of December 31, 2009. This change primarily resulted from the use of cash for research and development as well as general and administrative expenses, offset by $3.0 million received from VGX International in connection with the March 2010 Collaboration and License Agreement.

In 2010 Inovio issued 1,994,672 shares at an average price of $1.20 per share with net proceeds to the Company of $2.3 million. These shares were sold under an At-the-Market Equity Offering, the details of which were filed with the SEC under Form 8-K on August 27, 2010. This Offering allows the company to sell shares from time to time at its discretion through an agent into the market.

In January 2011 the Company entered into an investor purchase agreement with a single investor relating to the issuance and sale of (a) 21,130,400 shares of common stock and (b) warrants to purchase a total of 10,565,200 shares of common stock with an exercise price of $1.40 per share, for an aggregate purchase price of approximately $24.3 million. The shares of common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock. The purchase price for the share and warrant was $1.15 per unit. The Company received net proceeds from the transaction of approximately $23.0 million after deducting the placement agent's fee and estimated offering expenses payable by the Company.

The number of shares of common stock issued and outstanding was 127,254,
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
4. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
6. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
7. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
8. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
9. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
10. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
11. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Israele, February 27, 2015 ... sviluppo dell,innovativo sistema di monitoraggio dell,infarto congestizio (CHF ... sull,uomo-     ... di nuovo sistema per il monitoraggio cardiaco destinato ... annunciato oggi di aver concluso una raccolta di ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)... 2015 An aggressive campaign to reduce the ... of infection with a dangerous drug-resistant bacteria at The ... difficile, or C.diff, is a bacterium that can cause ... colon. A recent article in the New England Journal ... the United States " asserts that ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
(Date:3/1/2015)... March 01, 2015 The number of ... over the past few weeks in two New Jersey ... filing claims, the Firm announces. , A Case ... in the Bergen County proceeding established for products manufactured ... a few weeks earlier, when 90 fewer cases had ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 2015 Vancouver personal injury lawyers at Jiwa ... affected by time limits. They stated that in many cases, ... or even nullify it. Many a time, delays in making ... rights under BC law. As a result, experts at Jiwa ... should consult a personal injury lawyer in order to know ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2
... Steven Reinberg HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... -- defined as men who down five or more drinks at ... one time, federal researchers reported Tuesday. Of the 17 percent ... 24 years old. But those 65 and older engage in the ...
... , INDIANAPOLIS -- The School of Science at Indiana ... Modeling and Computational Science, an interdisciplinary endeavor dedicated to ... the environment, and computer science. iM2CS,s parallel mission is ... the scientific issues with which they will be faced. ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Dutch researchers ... the drug Nexavar (sorafenib) in fighting a tough-to-treat form ... experimental drug known as ganetespib showed promise in laboratory ... studies were to be presented Tuesday at an American ...
... Island Hospital has found that collaborative ,behavioral management may ... users who are paroled. The findings have important implications ... U.S. community correctional population. The study is published in ... of print. In the U.S., over 700,000 inmates ...
... January issue of Health Affairs assesses real-world ... chronic disease that affects nearly 26 million Americans. ... systematically reviewed the published literature and analyzed 28 studies ... trial in real-world settings. Published in 2002, this major ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- The ... the risk of heart attack, a new review finds. ... trials involving Pradaxa that included more than 30,000 patients. This ... to tease out a pattern that might not show up ...
Cached Medicine News:Health News:One in Six Americans Binge Drink: CDC 2Health News:One in Six Americans Binge Drink: CDC 3Health News:Revealing causality 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 2Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 3Health News:Diabetes study shines spotlight on lifestyle interventions 2Health News:Diabetes study shines spotlight on lifestyle interventions 3Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3
... first instrument engineered to match the speed ... cycling system is based on heat transfer ... microcapillary tubes or thin walled micorcentrifuge tubes. ... of high velocity air results in nearly ...
... Excellent performance, small footprint, simple intuitive ... the Primus 25 the ideal personal cycler ... ,The flexiblock design and the self-adjusting heated ... or 13x 0.5ml vessels or a microplate ...
... day-to-day temperature cycling ,Unmatched ... ,30% reduction in cycling ... coolant-based cyclers ,4 programmable ... ,Options for oil-free and ...
... rapid, real-time thermal cycler used for identifying ... much of the testing process, and making ... the fastest, easiest to use, and most ... SmartCycler delivers highly accurate and consistent test ...
Medicine Products: